TNFRSF17 and Miyoshi myopathy: Notably, four of these CAR-T cell products target anti-cluster of Differentiation (CD)19, while the two most recent ones focus on B-cell maturation antigen (BCMA) and have achieved rapid and durable responses in patients with R/R- ALL, FL, MCL, DLBCL, CLL, and MM (10–18).